Managing Malaria-Induced Iron Deficiency: A Case Study

Select Content Type
Resources
Authored By
Shalina MedSpace
Authored On
Interests
Cardiology
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pediatric Medicine
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Speciality
Cardiology
Dentistry
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Geriatrics
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Medical Genetics
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pathology
Pediatric Medicine
Pharmacology
Psychiatry
Public Health
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Thumbnail Image
Hemoforce plus_thumbnail
Detail Image
Hemoforce plus_detail
Book Detail
Upload PDF
Actions
Download in App
Promotional Categories
Featured
Countries of release
Angola
Central African Republic (CAR)
Democratic Republic of the Congo (DRC)
Ghana
India
Kenya
Nigeria
UAE
Zambia
IS_Ebsco
false
Description

One of the common causes of Iron Deficiency Anemia (IDA) in Africa is malaria, resulting from the hemolysis of both infected and uninfected red blood cells. Additionally, preexisting iron deficiency can further impact recovery from post-malarial anemia. 

This case review CME presents the diagnosis and management of a 28-year-old male who reported with fatigue and dizziness and was diagnosed with IDA following a malaria episode. Considering the high burden of post-malarial anemia in sub-Saharan Africa and the potential contribution of G6PD deficiency to red cell destruction, timely oral iron therapy was initiated. The patient was treated with Hemoforce Plus, a combination of ferric ammonium citrate (FAC), vitamins and minerals, chosen for its better gastrointestinal tolerability and enhanced hematologic response compared to conventional iron salts. After one month, the patient reported complete symptom relief, with a rise in hemoglobin level, indicating effective recovery and improved compliance.

Published Date